BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist 2009;14:83-91. [PMID: 19126579 DOI: 10.1634/theoncologist.2008-0189] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;56:595-603. [PMID: 21298745 DOI: 10.1002/pbc.22741] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
2 Bonvini P, Zin A, Alaggio R, Pawel B, Bisogno G, Rosolen A. High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma. Br J Cancer 2013;109:3084-91. [PMID: 24149177 DOI: 10.1038/bjc.2013.653] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
3 Cheng L, Pandya PH, Liu E, Chandra P, Wang L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR, Bijangi-Visheshsaraei K, Marshall M, Li L, Pollok KE, Renbarger JL. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Med Genomics 2019;12:23. [PMID: 30704460 DOI: 10.1186/s12920-018-0456-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
4 Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs 2013;15:473-92. [PMID: 23760780 DOI: 10.1007/s40272-013-0037-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010;16:183-94. [PMID: 20526094 DOI: 10.1097/PPO.0b013e3181dbebf9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
6 Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov 2017;7:884-99. [PMID: 28446439 DOI: 10.1158/2159-8290.CD-16-1297] [Cited by in Crossref: 116] [Cited by in F6Publishing: 76] [Article Influence: 23.2] [Reference Citation Analysis]
7 Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009;8:2122-30. [PMID: 19638450 DOI: 10.1158/1535-7163.MCT-09-0115] [Cited by in Crossref: 59] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
8 Venkatramani R, Furman WL, Fuchs J, Warmann SW, Malogolowkin MH. Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs 2012;14:221-32. [PMID: 22702740 DOI: 10.2165/11597740-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
9 Coyne GS, Kenny DA, Waters SM. Effect of dietary n-3 polyunsaturated fatty acid supplementation on bovine uterine endometrial and hepatic gene expression of the insulin-like growth factor system. Theriogenology 2011;75:500-12. [PMID: 21111466 DOI: 10.1016/j.theriogenology.2010.09.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
10 Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer 2014;61:749-52. [PMID: 24178953 DOI: 10.1002/pbc.24778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Jürgens H, Dirksen U. Ewing sarcoma treatment. Eur J Cancer 2011;47 Suppl 3:S366-7. [PMID: 21944018 DOI: 10.1016/S0959-8049(11)70206-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Rossi S, Poliani PL, Missale C, Monti E, Fanzani A. Caveolins in rhabdomyosarcoma. J Cell Mol Med 2011;15:2553-68. [PMID: 21707915 DOI: 10.1111/j.1582-4934.2011.01364.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 2009;52:4981-5004. [PMID: 19610618 DOI: 10.1021/jm9002395] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
14 De Giovanni C, Landuzzi L, Nicoletti G, Lollini P, Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncology 2009;5:1449-75. [DOI: 10.2217/fon.09.97] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
15 Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013;14:e117-e124. [PMID: 23434337 DOI: 10.1016/s1470-2045(13)70013-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 20] [Article Influence: 7.4] [Reference Citation Analysis]
16 Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res 2015;21:1558-65. [PMID: 25467181 DOI: 10.1158/1078-0432.CCR-14-0595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
17 Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res 2012;18:2423-8. [PMID: 22427348 DOI: 10.1158/1078-0432.CCR-11-1409] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
18 Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N; COG Bone Tumor Committee. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 2013;60:1009-15. [PMID: 23255238 DOI: 10.1002/pbc.24429] [Cited by in Crossref: 106] [Cited by in F6Publishing: 86] [Article Influence: 10.6] [Reference Citation Analysis]
19 Kenny C, McDonagh N, Lazaro A, O'Meara E, Klinger R, O'Connor D, Roche F, Hokamp K, O'Sullivan MJ. Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney. J Pathol 2018;244:334-45. [PMID: 29243812 DOI: 10.1002/path.5020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62:199-236. [PMID: 20392809 DOI: 10.1124/pr.109.002469] [Cited by in Crossref: 141] [Cited by in F6Publishing: 139] [Article Influence: 11.8] [Reference Citation Analysis]
21 Merchant MS, Mackall CL. Current approach to pediatric soft tissue sarcomas. Oncologist. 2009;14:1139-1153. [PMID: 19897537 DOI: 10.1634/theoncologist.2009-0160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
22 Li T, Wang J, Liu P, Chi J, Yan H, Lei L, Li Z, Yang B, Wang X. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress. Oncotarget 2017;8:47269-83. [PMID: 28521298 DOI: 10.18632/oncotarget.17617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Dong L, Du M, Lv Q. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway. Acta Biochim Biophys Sin (Shanghai) 2019;51:753-60. [PMID: 31168597 DOI: 10.1093/abbs/gmz055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29:4541-7. [PMID: 22025149 DOI: 10.1200/JCO.2010.34.0000] [Cited by in Crossref: 211] [Cited by in F6Publishing: 143] [Article Influence: 19.2] [Reference Citation Analysis]
25 Sung B, Prasad S, Yadav VR, Aggarwal BB. Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer 2012;64:173-97. [PMID: 22149093 DOI: 10.1080/01635581.2012.630551] [Cited by in Crossref: 116] [Cited by in F6Publishing: 98] [Article Influence: 10.5] [Reference Citation Analysis]
26 Majo VJ, Arango V, Simpson NR, Prabhakaran J, Kassir SA, Underwood MD, Bakalian M, Canoll P, John Mann J, Dileep Kumar JS. Synthesis and in vitro evaluation of [18F]BMS-754807: a potential PET ligand for IGF-1R. Bioorg Med Chem Lett 2013;23:4191-4. [PMID: 23743281 DOI: 10.1016/j.bmcl.2013.05.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
27 Zanola A, Rossi S, Faggi F, Monti E, Fanzani A. Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med 2012;16:1377-91. [PMID: 22225829 DOI: 10.1111/j.1582-4934.2011.01518.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
28 Hughes DP. Novel agents in development for pediatric sarcomas. Curr Opin Oncol 2009;21:332-7. [PMID: 19444103 DOI: 10.1097/CCO.0b013e32832c94e2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hingorani P, Kolb EA. Past, present and future of therapies in pediatric sarcomas. Future Oncol 2010;6:605-18. [PMID: 20373872 DOI: 10.2217/fon.10.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sulzbacher I, Birner P, Dominkus M, Pichlhofer B, Mazal PR. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology 2010;42:664-8. [PMID: 21080877 DOI: 10.3109/00313025.2010.520310] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
31 Daqian W, Chuandong W, Xinhua Q, Songtao A, Kerong D. Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling. Chemico-Biological Interactions 2015;237:25-30. [DOI: 10.1016/j.cbi.2015.05.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
32 Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. The contrasting age-incidence patterns of bone tumours in teenagers and young adults: Implications for aetiology. Int J Cancer 2012;131:1678-85. [PMID: 22174047 DOI: 10.1002/ijc.27402] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
33 Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin Cancer Res 2013;19:2984-94. [PMID: 23549869 DOI: 10.1158/1078-0432.CCR-12-2008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Soundararajan A, Abraham J, Nelon LD, Prajapati SI, Zarzabal LA, Michalek JE, McHardy SF, Hawkins DS, Malempati S, Keller C. 18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models. Pediatr Blood Cancer 2012;59:485-92. [PMID: 22238194 DOI: 10.1002/pbc.24075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
35 Hernández-Breijo B, Monserrat J, Román ID, González-Rodríguez Á, Fernández-Moreno MD, Lobo MV, Valverde ÁM, Gisbert JP, Guijarro LG. Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. Toxicol Appl Pharmacol. 2013;272:568-578. [PMID: 23958494 DOI: 10.1016/j.taap.2013.07.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
36 Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int. 2015;2015:538019. [PMID: 25866791 DOI: 10.1155/2015/538019] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 16.1] [Reference Citation Analysis]
37 Ackermann M, Morse BA, Delventhal V, Carvajal IM, Konerding MA. Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 2012;15:685-95. [DOI: 10.1007/s10456-012-9294-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
38 McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011;30:4910-20. [PMID: 21643012 DOI: 10.1038/onc.2011.197] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
39 Flores LG 2nd, Yeh HH, Soghomonyan S, Young D, Bankson J, Hu Q, Alauddin M, Huff V, Gelovani JG. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth. Mol Imaging Biol 2013;15:175-85. [PMID: 22875335 DOI: 10.1007/s11307-012-0588-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
40 Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54. [PMID: 21385891 DOI: 10.1124/jpet.110.178400] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
41 Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE. Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models. Invest New Drugs 2020;38:1677-86. [DOI: 10.1007/s10637-020-00933-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA, Arcaro A. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One 2012;7:e47109. [PMID: 23056595 DOI: 10.1371/journal.pone.0047109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
43 Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 2010;25:683-91. [PMID: 20205169 DOI: 10.1002/jbmr.77] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
44 . Current Opinion in Oncology. Current world literature. Curr Opin Oncol 2009;21:386-92. [PMID: 19509503 DOI: 10.1097/CCO.0b013e32832e] [Reference Citation Analysis]
45 Chandhanayingyong C, Kim Y, Staples JR, Hahn C, Lee FY. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. Sarcoma 2012;2012:404810. [PMID: 22577336 DOI: 10.1155/2012/404810] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
46 Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, Luu HH. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2015;2:13-25. [PMID: 25984556 DOI: 10.1016/j.gendis.2014.10.004] [Cited by in Crossref: 193] [Cited by in F6Publishing: 177] [Article Influence: 27.6] [Reference Citation Analysis]
47 Chang CH, Wang Y, Trisal P, Li R, Rossi DL, Nair A, Gupta P, Losman M, Cardillo TM, Rossi EA, Goldenberg DM. Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS One 2012;7:e44235. [PMID: 22952934 DOI: 10.1371/journal.pone.0044235] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
48 Manara MC, Terracciano M, Mancarella C, Sciandra M, Guerzoni C, Pasello M, Grilli A, Zini N, Picci P, Colombo MP, Morrione A, Scotlandi K. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget 2016;7:79925-42. [PMID: 27835596 DOI: 10.18632/oncotarget.13160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
49 Reimann E, Kõks S, Ho XD, Maasalu K, Märtson A. Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum Genomics 2014;8:20. [PMID: 25496518 DOI: 10.1186/s40246-014-0020-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
50 Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer 2016;62:9-17. [PMID: 27185573 DOI: 10.1016/j.ejca.2016.03.084] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
51 Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim Biophys Acta 2014;1845:266-76. [PMID: 24582852 DOI: 10.1016/j.bbcan.2014.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
52 Vewinger N, Huprich S, Seidmann L, Russo A, Alt F, Bender H, Sommer C, Samuel D, Lehmann N, Backes N, Roth L, Harter PN, Filipski K, Faber J, Paret C. IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients. Int J Mol Sci 2019;20:E3027. [PMID: 31234291 DOI: 10.3390/ijms20123027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
53 Subbiah V, Anderson P. Targeted Therapy of Ewing's Sarcoma. Sarcoma 2011;2011:686985. [PMID: 21052545 DOI: 10.1155/2011/686985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
54 Huang HS, Chu SC, Chen PC, Lee MH, Huang CY, Chou HM, Chu TY. Insuline-Like Growth Factor-2 (IGF2) and Hepatocyte Growth Factor (HGF) Promote Lymphomagenesis in p53-null Mice in Tissue-specific and Estrogen-signaling Dependent Manners. J Cancer 2021;12:6021-30. [PMID: 34539876 DOI: 10.7150/jca.60120] [Reference Citation Analysis]
55 Zhao Q, Tran H, Dimitrov DS, Cheung NK. A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. Int J Cancer 2015;137:2243-52. [PMID: 25924852 DOI: 10.1002/ijc.29588] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
56 Geryk-Hall M, Hughes DP. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 2009;11:446-53. [PMID: 19840522 DOI: 10.1007/s11912-009-0061-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
57 Czifra G, Szöllősi A, Nagy Z, Boros M, Juhász I, Kiss A, Erdődi F, Szabó T, Kovács I, Török M, Kovács L, Blumberg PM, Bíró T. Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscle. J Cell Mol Med 2015;19:396-407. [PMID: 25283340 DOI: 10.1111/jcmm.12452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Wan X, Yeung C, Heske C, Mendoza A, Helman LJ. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma. Neoplasia 2015;17:358-66. [PMID: 25925378 DOI: 10.1016/j.neo.2015.03.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
59 Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Preclinical drug development for childhood cancer. Expert Opinion on Drug Discovery 2010;6:49-64. [DOI: 10.1517/17460441.2011.537652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
60 Yan Y, Hu F, Wu W, Ma R, Huang H. Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus. Medicine (Baltimore) 2017;96:e6393. [PMID: 28328831 DOI: 10.1097/MD.0000000000006393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010;15:615-34. [PMID: 20690888 DOI: 10.1517/14728214.2010.505603] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
62 Badr M, Hassan T, Tarhony SE, Metwally W. Insulin-like growth factor-1 and childhood cancer risk. Oncol Lett 2010;1:1055-9. [PMID: 22870112 DOI: 10.3892/ol.2010.169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
63 Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, Czerwitzki J, Steiner S, Renner M, Penzel R, Koch A, Larsson O, Tanaka S, Kawai A, Schirmacher P, Mechtersheimer G, Wardelmann E, Buettner R, Hartmann W. Phosphatidylinositol-3′-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer 2011;129:1564-75. [DOI: 10.1002/ijc.25829] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
64 Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012;33:1441-58. [PMID: 22983389 DOI: 10.1038/aps.2012.72] [Cited by in Crossref: 107] [Cited by in F6Publishing: 88] [Article Influence: 10.7] [Reference Citation Analysis]
65 Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20:R321-R339. [PMID: 24080445 DOI: 10.1530/erc-13-0231] [Cited by in Crossref: 158] [Cited by in F6Publishing: 111] [Article Influence: 17.6] [Reference Citation Analysis]
66 Pal A, Chiu HY, Taneja R. Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics. Redox Biol 2019;25:101124. [PMID: 30709791 DOI: 10.1016/j.redox.2019.101124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]